A long survival of a patient with brain metastasis of unknown site of the primary tumor by Ben Kridis, W. et al.
Experimental Oncology 40, 85–87, 2018 (March) 85
A LONG SURVIVAL OF A PATIENT WITH BRAIN METASTASIS 
OF UNKNOWN SITE OF THE PRIMARY TUMOR
W. Ben Kridis1, *, S. Sghaier1, N. Toumi1, Z. Boudawara2, A. Khanfir1, J. Daoud3, M. Frikha1
1Department of Oncology, Habib Bourguiba Hospital, Sfax 3029, Tunisia
2Department of Neurosurgery, Habib Bourguiba Hospital, Sfax 3029, Tunisia
3Department of Radiotherapy, Habib Bourguiba Hospital, Sfax 3029, Tunisia
Eighty percent of brain metastases (BM) are diagnosed in patients with known primary site of cancer. BM of unknown primary 
represents a difficult diagnosis. In up to 15% of patients with BM, the site of the primary tumor will not be detected despite in-
vestigations. The prognosis of this entity is very poor. We report here a case of a long survival of a patient with brain metastasis 
of unknown primary. The conclusion that can be drawn is that within BM of unknown primary exist patients with a very good 
prognosis that must be collected and published in order to base recommendations.
Key Words: brain metastases, unknown primary, prognosis.
Eighty percent of brain metastases (BM) are diag-
nosed in patients with known primary site of cancer. 
BM of unknown primary (BMUP) represents a difficult 
diagnosis [1, 2]. In up to 15% of patients with BM, the site 
of the primary tumor will not be detected despite investi-
gations [3]. Even though the primary remains undefined 
during the follow up, some of these patients found to have 
a favorable prognosis. In fact, cancer of unknown primary 
(CUP) has been divided into favorable group (20%) and 
unfavorable group (80%) based on histopathology and 
clinical manifestations [2]. We report here a case of an ex-
ceptional long survival of a patient with BMUP.
CASE REPORT
A 50-year-old man was referred to our hospital in Oc-
tober 2002 because of increased headaches, vomiting 
and dizziness evolving for two weeks. Glasgow score was 
quoted at 14/15. Neurological examination revealed ki-
netic cerebellar syndrome. Fundus examination revealed 
a peripapillary hemorrhage in the right eye. Brain mag-
netic resonance imaging (MRI) showed a 4 × 2 cm lesion 
of the right cerebellum with a T1 weighted hyposignal, 
T2 weighted hypersignal and a heterogeneous enhance-
ment. This lesion compressed the brainstem and the 
fourth ventricle causing a triventricle expansion with signs 
of active hydrocephalus (Fig. 1). The patient underwent 
a complete resection of the tumor. The pathologic study 
showed polyhedral tumor cells arranged in solid sheets 
with a clear abundant cytoplasm. The tumor stroma had 
a vascular component of endocrine type without necro-
sis. The antibody panel consisted of reagents directed 
to antigens: CK7, CK20, EMA, NSE, chromogranin, 
synaptophysin, glial fibrillary acidic protein (GFAP), TTF1, 
ACE and vimentin. The immunohistochemical staining 
was positive for vimentin, NSE, TTF1, CEA but negative 
for GFAP. These results were compatible with cerebellar 
metastasis from a clear cell carcinoma. After surgery, the 
patient maintained a minimal static cerebellar syndrome. 
Brain imaging showed no residual tumor. No whole brain 
radiation was delivered. In order to detect the primary 
cancer, lung auscultation, thyroid examination as well 
as organs of abdomen examination and digital rectal 
exam were normal. Full blood counts were normal. Total 
body computed tomography (CT) was normal. Bron-
chofibroscopy revealed an inflammatory aspect of the 
left bronchi and its biopsy showed chronic inflamma-
tion. Positron emission tomography (PET) scan was not 
available in 2002. Tumor markers levels including PSA, 
CEA, CA19-9, and NSE were also normal. The patient 
was discharged with physical examination and CT every 
4 months in the first year, then every six months during 
two years and then annually. In June 2014, CT scan re-
vealed a nonspecific 5 mm node in the right lung. Brain 
CT showed no recurrent disease (Fig. 2). Actually, our 
patient remains asymptomatic with no recurrent disease 
14 years after the diagnosis of BM.
Fig. 1. Cerebral MRI: cerebellar metastasis
Fig. 2. Cerebral CT: cerebellar porencephalic cavity after surgery 
with no recurrence
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DISCUSSION
The definition of CUP includes patients with histo-
logical confirmed metastatic cancer in whom a detailed 
medical history, thorough physical examination and 
complete laboratory investigations fail to identify the 
primary site [2]. This is due to the fact that the pre-
sumed primary tumor is able to metastasize before 
becoming large enough to be identified [7]. BMUP 
represents 15% of all BM [4–6]. In about 50% of BMUP 
cases, primary lung cancer is found to be the most 
frequent primary site (51%) [8]. Although the breast 
is the second most primary site in BM (10–17%). In the 
reported cases of BMUP, melanoma represented 8%, 
the pancreatic cancer was found in 8% and gastroin-
testinal cancers in 19% cases [9–12]. In our patient 
histopathological study with immunohistochemistry 
was compatible with cerebellar metastasis from a clear 
cell carcinoma. However, exploration did not find the 
primitive.
About 85% of BMUP are found in the cerebral 
hemispheres, 10–15% found in the cerebellum and 
3% in the brainstem. In our case, the BM was located 
in the right cerebellum. Certain primary tumors such 
as those originating from kidney and colon are more 
likely to metastasize to the cerebellum.
As for the clinical presentation, the mean age 
of BMUP’s patients ranges from 50 to 60 years with 
a male predilection. The predominant presenting 
symptom in BM is headaches as it is the case of our 
patient. Fifty percent of patients with BM have motor 
or language deficits and 10–15% of them present 
seizures [13]. Approximately, 10% of BM are asymp-
tomatic and the diseases’ spread is identified through 
routine imaging [14, 15].
The preferred modality for detecting brain lesions 
is MRI. Despite the accuracy of MRI, CT imaging is of-
ten used when MRI is either not available or not suit-
able for particular patients [16]. Despite the sensitivity 
of MRI, 11% of patients with a brain lesion are given 
a false-positive diagnosis of either a BM or a primary 
brain cancer [17–20].
The dilemma of distinguishing between a BM and 
a primary brain tumor can only be solved by biopsy 
or tumor resection with histopathological study [21, 
22]. The choice between biopsy and surgical resection 
depends on many factors: number of brain lesions, its 
location, patient’s general condition (Karnofsky per-
formance status — KPS, age, comorbidity) and pres-
ence or not of accessible extra-cranial metastases. 
In our case, cerebral MRI showed a single lesion of the 
right cerebellum, so that he underwent a complete 
resection of the tumor.
In order to detect the primary cancer, physical 
examination was normal. Full blood counts were nor-
mal. Total body CT was normal. Bronchofibroscopy 
revealed an inflammatory aspect of the left bronchi 
and its biopsy showed chronic inflammation. PET scan 
was not available in 2002. Nowadays, the combination 
of PET/CT plays an important role to search the primi-
tive in case of CUP [23, 24].
In our case, the immunohistochemical staining was 
positive for vimentin, NSE, TTF1, CEA but negative for 
GFAP. These results concluded to cerebellar metasta-
sis from a clear cell carcinoma.
In the study of Drlicek et al. [25], 40 cases 
of BM from known primary tumors were blinded and re-
evaluated based on the immunohistochemical staining 
pattern. An established panel of antibodies was used 
including: CK AE1/AE3, CK7, CK20, CK10/13, CK18, 
vimentin, S100, TTF-1, surfactant, PSA, CA15-3, 
CA125, and CA19-9. This panel of 13 different an-
tibodies was able to identify the primary in 29 out 
of 40 BM correctly (72.5%). In this series, 1/11 of lung 
cancer BM had a CK7 negative-CK20 negative profile.
The treatment of BM is an oncologic emergency. The 
recommendation of the subcommittee of the American 
Academy of Neurology (AAN) is that in patients with newly 
diagnosed brain tumor prophylactic anticonvulsants 
should not be used, it has to be initiated from the time 
of the first seizure [26]. For patients who undergo surgery, 
AAN recommends to stop them in 1 to 4 weeks postop-
eratively. All patients should have corticotherapy. Patients 
with single BM, good KPS and no disseminated disease, 
should have surgery or radiosurgery (if lesion less than 
3 cm) to achieve local tumor control. Radiosurgery is less 
invasive and gives the same result as with surgery but 
it does not provide tissue diagnosis. Postoperative whole 
brain radiation therapy (WBRT) helps to sterilize the other 
areas and improves survival [18]. In case of multiple BM, 
WBRT is given usually in doses of 30 Gy in 10 fractions 
or 20 Gy in 5 fractions. Chemotherapy has a relatively 
small role in case of BMUP. In fact, only few molecules 
could cross the blood-brain barrier.
Our patient was aged less than 65 years, he had 
a KPS > 70, his BM was single and completely resected 
and finally, he had no other metastases. All these fac-
tors explain the good evolution and the long survival 
of this patient [27, 28].
In a retrospective study, the median overall survival 
for patients with a solitary BMUP was 7.3 vs 3.9 months 
for patients with multiple metastases (p = 0.05). Pa-
tients who underwent resection of BM before WBRT 
had a significant better overall survival than those who 
underwent WBRT alone (9.5 vs 3.6 months median sur-
vival, respectively) [15]. The majority of these patients 
die from extracranial disease and only a minority (15%) 
will live more than five years [29]. To our knowledge, 
our patient represents the first case described in the 
literature with an overall survival exceeding 10 years.
CONCLUSIONS
BMUP is an ambiguous disease. It poses a problem 
for the oncological patient and his doctor. The progno-
sis of this entity is very poor. This case is exceptional; 
firstly given its rarity and secondly due to the long sur-
vival that exceeded 10 years. The conclusion that can 
be drawn is that within BMUP exist patients with a very 
good prognosis that must be collected and published 
in order to base recommendations.
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